Form 4: Enliven Therapeutics Director Sells Shares Under 10b5-1 Plan

Enliven Therapeutics Director Richard A. Heyman reported the sale of common stock totaling 13,920 shares through pre-arranged Rule 10b5-1 trading plans in early January 2026.

Summary

• Director Richard A. Heyman reported sales of Enliven Therapeutics, Inc. common stock.
• Transactions occurred on January 8, 2026, and January 9, 2026.
• Sales were executed under Rule 10b5-1 trading plans adopted on November 15, 2024.
• On January 8, 2026, 1,620 shares were sold at $25.00 by RAHD Capital LLC, leaving 25,545 shares beneficially owned by RAHD Capital LLC.
• On January 8, 2026, 8,015 shares were sold at a weighted average price of $25.035 by the Heyman Daigle Trust, leaving 29,392 shares beneficially owned by the Trust.
• On January 9, 2026, 4,285 shares were sold at a weighted average price of $25.0001 by the Heyman Daigle Trust, leaving 25,107 shares beneficially owned by the Trust.
• Heyman directly owns 123,673 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled insider stock sales under a 10b5-1 plan, which is a neutral event and does not reflect positively or negatively on the company's operational performance or future prospects.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This routine insider transaction filing does not provide specific insights into broader industry trends or competitive landscape for Enliven Therapeutics, which operates in the biotechnology sector.

Stakeholder Impact

• Shareholders: Minor impact as these are pre-scheduled sales, indicating a planned diversification or liquidity event by a director rather than a reaction to new company-specific information.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Sale, Richard A. Heyman, 10b5-1 Plan, Director, Biotechnology